IGC Pharma, Inc. (IGC): Cost of Revenue
Not updated since 2025-03-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$652.0K
Year ended 2025-03-31
$595.0K
Trailing 12 months to 2025-09-30
+47.5%
3-year compound annual growth
-30.3%
5-year compound annual growth
-21.2%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-03-31 | $652.0K | +6.5% | 2025-06-27, From 2024-04-01 |
| 2024-03-31 | $612.0K | +30.5% | 2025-06-27, From 2023-04-01 |
| 2023-03-31 | $469.0K | +131.0% | 2024-06-24, From 2022-04-01 |
| 2022-03-31 | $203.0K | -74.1% | 2023-07-07, From 2021-04-01 |
| 2021-03-31 | $785.0K | -80.2% | 2022-06-23, From 2020-04-01 |
| 2020-03-31 | $3.96M | -20.6% | 2021-06-14, From 2019-04-01 |
| 2019-03-31 | $4.98M | +136.1% | 2020-07-13, From 2018-04-01 |
| 2018-03-31 | $2.11M | +482.9% | 2019-06-14, From 2017-04-01 |
| 2017-03-31 | $362.1K | -93.4% | 2018-06-21, From 2016-04-01 |
| 2016-03-31 | $5.52M | -22.2% | 2017-07-14, From 2015-04-01 |
| 2015-03-31 | $7.10M | +275.4% | 2016-07-14, From 2014-04-01 |
| 2014-03-31 | $1.89M | -70.9% | 2015-07-14, From 2013-04-01 |
| 2013-03-31 | $6.50M | +34.8% | 2014-07-15, From 2012-04-01 |
| 2012-03-31 | $4.82M | +23.1% | 2014-07-15, From 2011-04-01 |
| 2011-03-31 | $3.91M | n/a | 2012-07-16, From 2010-04-01 |